COSM Cosmos Health Inc.

Cosmos Health Inc.

Other Pharmaceuticals

Health Care

Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.

IPO Year:

Exchange: NASDAQ

Website: https://www.cosmosholdingsinc.com

Recent Analyst Ratings for Cosmos Health Inc.

Date	Price Target	Rating	Analyst

See more ratings

Cosmos Health Inc. Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
CHICAGO, IL / ACCESSWIRE / November 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has adopted a strategy to include Bitcoin and Ethereum as part of its treasury reserve assets.The adoption of this new policy follows the Company's forward-thinking approach to investing in new technologies, including the recent acquisition of Cloudscreen, its AI-driven drug repurposing platform.The Company expects
11/18/24 8:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash and cash equivalents exceeding $3.3 million.Hard assets, mainly comprised of debt-free properties, valued at over $12 million; exceeding total debt and providing financing flexibility.Liquid inventory position and accounts receivable that are collected at an accelerated pace provide additional flexibility.Record-breaking results at CosmoFarm and in Amazon UK sales.Various cost-cutting and efficiency initiatives are underway as revenue accelerates, with a focus on high-margin segments like CMO and proprietary brands.CHICAGO, IL / ACCES
11/14/24 5:00:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone
11/12/24 12:01:41 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its healthcare distribution business, operated through its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), has achieved record sales.In the first ten months of 2024, CosmoFarm achieved record revenue of approximately $43 million, representing an 8.62% increase over the same period last year and contributing to a
11/1/24 12:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by 160%, increasing to $596,000 year-to-date in 2024 from $230,000 during the same period in 2023.Greg Siokas, CEO of Cosmos Health, stated: "We are delighted that our proprietary brands are being very well receive
9/25/24 9:25:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received its first round of purchase orders in the United Kingdom (UK) for its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ('C-Scrub'), exceeding $500,000. The orders cover the period from July 2024 to September 2024.Cosmos Health is in the process of securing additional orders for October 2024 and beyond
9/23/24 12:55:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an exclusivity agreement with Virax Biolabs to distribute mpox (formerly monkeypox) virus real-time PCR detection kits across India.With a population of over 1.4 billion, India is an important region where enhanced detection capabilities are needed. Following the second reported case of mpox on Sep
9/23/24 9:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
CHICAGO, IL / ACCESSWIRE / September 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its updated guidance for the 2024-2027 period.Key highlights of the guidance include:Revenue is projected to increase by 163%, from $59.35 million in 2024 to $155.80 million in 2027.Gross profit is expected to rise by 653%, from $6.25 million in 2024 to $47.06 million in 2027.Gross profit margin is anticipated to expand by
9/18/24 1:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
CHICAGO, IL / ACCESSWIRE / September 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on September 16, 2024, Taglich Brothers, Inc. ("Taglich Brothers") published its updated research report on the Company's common stock.Key highlights of Taglich Brothers' updated coverage report include:Maintains Speculative Buy rating with a $4 price target, implying a nearly four-fold share price increase over the n
9/17/24 11:45:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (NASDAQ:VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as
9/16/24 8:30:00 AM ET
$COSM
$VRAX
Other Pharmaceuticals
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded
11/21/23 9:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor
CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the engagement of KPMG Certified Auditors S.A. ("KPMG") as the Company's independent registered public accounting firm, effective August 7, 2023. KPMG replaces the Company's former auditor, Armanino LLP.The appointment of KPMG was made by the Cosmos Health Board of Directors at the recommendation of its Audit Committee. The decision to change auditors was not the result of any disagreement between the Company
8/8/23 9:20:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer
CHICAGO, IL / ACCESSWIRE / February 1, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the appointment of Nikos Bardakis, who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).As the Chief Operating Officer at Cosmos Health, Mr. Bardakis' objective will be to bring new capabilities and processes into the organization for optimizing operational excellence towards global commercial expansion of Cosmos' premium products. In addition, M
2/1/23 11:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board
CHICAGO, IL / ACCESSWIRE / July 22 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has appointed finance veteran Dr. Manfred Ziegler to the Company's Advisory Board.Dr. Ziegler brings over 30 years of executive management, financial, and operational experience, as well as extensive expertise in mergers and acquisitions, with a particular focus on high-growth public and private companies. Notably, Dr. Manfred Ziegler served as Chief Executive Officer of CC Pharma, a l
7/22/22 9:15:00 AM ET
$COSM
$APHA
Other Pharmaceuticals
Health Care
Specialty Chemicals
Consumer Durables
Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board's Audit Committee
CHICAGO, IL / ACCESSWIRE / May 3, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced it has appointed finance veteran Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board's audit committee.Dr. Anastasios Aslidis currently serves as the Chief Financial Officer and Treasurer, as well as a member of the Board of Directors of EuroDry (EDRY) since 2018. He is Chief Financial Officer, Treasurer and a member of the Board of Directors of Euroseas (NASDAQ:ESEA) si
5/3/22 9:15:00 AM ET
$COSM
$ESEA
Other Pharmaceuticals
Health Care
Marine Transportation
Consumer Discretionary

Cosmos Health Inc. Financials

Live finance-specific insights

Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone
11/12/24 12:01:41 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform.As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen. Building on the success of its predecessor, Cloudscreen 2.0 represents a sign
3/21/24 9:45:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of Cloudscreen®, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023.Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new tar
1/23/24 1:05:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for €3.2 million, or approximately $3.5 million at today's exchange rate.This strategic acquisition significantly enhances Cosmos Health's pharmaceutical portfolio. The selected d
1/18/24 9:25:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income
CHICAGO, IL / ACCESSWIRE / May 17, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2023.First Quarter 2023 Financial HighlightsRevenues amounted to $12.35 million, compared to $13.07 million in Q1 2022. When considered on a constant currency basis, using quarterly average Q1 2022 exchange rates, revenues were virtually flat at $13.03 million, highlighting the stability of our platform.Adjusted EBITDA was $0.4
5/17/23 8:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders
CHICAGO, IL / ACCESSWIRE / May 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"), a fully licensed pharmaceutical wholesale company operating in the western part of Athens, Greece.The CosmoFarm property, pictured below, comprises an entire 3-story building, 2,700 square meters (or approximately 29,063 square feet) in size. The purchase price was €966,000
5/3/23 1:35:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.
CHICAGO, IL / ACCESSWIRE / April 3, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has successfully completed the acquisition of ZipDoctor, Inc. ("ZipDoctor") from American International Holdings Corp (AMIH). The financial terms of the acquisition were not disclosed.ZipDoctor is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioural health
4/3/23 11:55:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Announces Application for Dual Listing on Upstream
CHICAGO, IL / ACCESSWIRE / February 2, 2023 / Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ").The planned dual listing on Upstream is designed to provide Cosmos Health the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, increasing liquidity a
2/2/23 1:50:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon in the United States
First commercial launch of the Company's nutraceutical products in the U.S. follows successful launches on Amazon in other key marketsCHICAGO, IL / ACCESSWIRE / June 2 , 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that the Company's subsidiary, SkyPharm S.A., a pharmaceutical wholesaler and distributor, is launching Sky Premium Life products on Amazon in the United States. Cosmos expects to introduce fifteen Sky Premium Life SKUs in the third quarter of 2022, and targets h
6/2/22 9:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022
Reports Positive Net Income of $0.2 Million and $1.2 Million of EBITDA for the First Quarter of 2022CHICAGO, IL / ACCESSWIRE / May 18, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2022.Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, "I am pleased to report revenue increased 12.5% to $13.1 million, gross profit increased 88.9% to $1.89 million and we achieved profitability
5/18/22 8:30:00 AM ET
$COSM
Other Pharmaceuticals
Health Care

Cosmos Health Inc.

Recent Analyst Ratings for Cosmos Health Inc.

Cosmos Health Inc.

Recent Analyst Ratings for Cosmos Health Inc.

Cosmos Health Inc. SEC Filings

Cosmos Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

SEC Form DEFA14A filed by Cosmos Health Inc.

SEC Form S-1 filed by Cosmos Health Inc.

SEC Form DEF 14A filed by Cosmos Health Inc.

SEC Form PRER14A filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form 424B3 filed by Cosmos Health Inc.

Cosmos Health Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Siokas Grigorios bought $49,806 worth of shares (60,000 units at $0.83), increasing direct ownership by 4% to 1,394,597 units (SEC Form 4)

Siokas Grigorios bought $158,806 worth of shares (6,712 units at $23.66), increasing direct ownership by 0.51% to 1,334,597 units (SEC Form 4)

Cosmos Health Inc. Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ

Cosmos Health Issues Letter to Shareholders

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins

Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Cosmos Health Inc. Market Insights

Live Market Insights

Cosmos Health's Subsidiary Cana Laboratories Completes Phase I Of Manufacturing Upgrades; Positioned To Generate Over $10M In Recurring Annual Gross Profit By End Of 2025

Cosmos Health Regains Compliance With Nasdaq Minimum Bid Price Rule

Cosmos Health shares are trading higher after the company announced its subsidiary, Cana Laboratories, secured additional contract manufacturing agreements with Provident Pharmaceuticals.

Cosmos Health's Subsidiary Cana Laboratories Secures Additional Contract Manufacturing Agreements With Provident Pharmaceuticals; Provident Focuses On Niche And Legacy Pharmaceutical Products And Medical Devices

Cosmos Health Announces Successful Completion Of Pilot Production And Scale-Up Phases Of CCX0722, A Biocompatible Hydrogel For Weight Management

Cosmos Health's Cana Secures Contract Manufacturing Agreement With Australia's Humacology For Up To 500,000 CBD Units Annually

Cosmos Health Signs Distribution Agreement With ZENDON s.r.o. In Slovakia, Hungary, Poland, And Czechia For Its Sky Premium Life Nutraceutical Products; Gains Access To More Than 6,000 Stores Of Pharmacy And Retail Chains

Why Cosmos Health Stock Is Trading Higher Friday

Cosmos Health shares are trading higher after the company signed an exclusive distribution agreement with Pharmalink for its Sky Premium Life products in the UAE, with an initial purchase order for 130,000 units.

Cosmos Health shares are trading higher after the company signed an exclusive distribution agreement with Pharmalink for its Sky Premium Life products in the UAE, with an initial purchase order for 130,000 units.

Cosmos Health Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

SEC Form SC 13D/A filed by Cosmos Holdings Inc. (Amendment)

SEC Form SC 13D filed by Cosmos Holdings Inc.

SEC Form SC 13D/A filed by Cosmos Holdings Inc. (Amendment)

SEC Form SC 13D filed by Cosmos Holdings Inc.

Cosmos Health Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Siokas Grigorios bought $49,806 worth of shares (60,000 units at $0.83), increasing direct ownership by 4% to 1,394,597 units (SEC Form 4)

Aslidis Anastasios returned $293 worth of shares to the company (200 units at $1.46), decreasing direct ownership by 0.99% to 20,000 units (SEC Form 4)

Terzis Georgios was granted 51,485 shares, increasing direct ownership by 51% to 152,459 units (SEC Form 4)

Siokas Grigorios bought $158,806 worth of shares (6,712 units at $23.66), increasing direct ownership by 0.51% to 1,334,597 units (SEC Form 4)

SEC Form 3: New insider Bhutawala Suhel claimed ownership of 5,000 shares

SEC Form 4: Aslidis Anastasios was granted 20,000 shares, increasing direct ownership by 10,000% to 20,200 units

SEC Form 3: New insider Ziegler Manfred claimed no ownership of stock in the company

SEC Form 4: Ziegler Manfred was granted 5,000 shares

SEC Form 4: Hoidas John James was granted 5,000 shares

SEC Form 4: Bardakis Nikolaos was granted 10,000 shares

Cosmos Health Inc. Leadership Updates

Live Leadership Updates

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer

Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board

Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board's Audit Committee

Cosmos Health Inc. Financials

Live finance-specific insights

Cosmos Health Issues Letter to Shareholders

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio

Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income

Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders

Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.